{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:57:43Z","timestamp":1791489463287,"version":"4.3.4"},"reference-count":37,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Context: Ovarian hyperstimulation syndrome (OHSS) results from increased vascular permeability (VP) caused by ovarian hypersecretion of vascular endothelial growth factor (VEGF), which activates its receptor-2. In animals, the dopamine receptor 2 agonist cabergoline (Cb2) inactivates VEGF receptor-2 and prevents increased VP.<\/jats:p>\n               <jats:p>Objective: Our objective was to test whether Cb2 reduces VP and prevents OHSS in humans.<\/jats:p>\n               <jats:p>Design: We conducted a prospective, randomized, double-blind study on oocyte donors at risk of developing OHSS (&amp;gt;20 follicles, &amp;gt;12 mm developed, and &amp;gt;20 oocytes retrieved).<\/jats:p>\n               <jats:p>Interventions: Cb2 0.5 mg\/d (n = 37) or a placebo (n = 32) was administered from the day of human chorionic gonadotropin (d 0) until d 8. Ascites (a pocket of peritoneal fluid &amp;gt; 9 cm2 in lithotomy position), hemoconcentration, and serum prolactin were recorded. Pharmacokinetic studies with magnetic resonance employing the transfer constant rate (Ktrans, measure of permeability) and the extravascular extracellular space (\u03c5e, marker of cellular leakage) were performed to measure VP objectively.<\/jats:p>\n               <jats:p>Results: Hematocrit (P &amp;lt; 0.01), hemoglobin (P = 0.003), and ascites (P = 0.005) were significantly lower on d 4 and 6 after treatment with Cb2 as compared with placebo. The incidence of moderate OHSS was 20.0 and 43.8%, respectively (P = 0.04). Magnetic resonance studies showed an increase in VP and extravascular leakage of fluid 5 d after human chorionic gonadotropin injection that was significantly prevented with Cb2 (KtransP = 0.04 and \u03c5eP = 0.001, respectively).<\/jats:p>\n               <jats:p>Conclusions: Given that Cb2 is a well-established and safe medication, this study provides proof of concept for the use of dopamine agonists in the prevention of OHSS in women undergoing assisted reproduction.<\/jats:p>","DOI":"10.1210\/jc.2007-0409","type":"journal-article","created":{"date-parts":[[2007,4,25]],"date-time":"2007-04-25T02:09:44Z","timestamp":1177466984000},"page":"2931-2937","source":"Crossref","is-referenced-by-count":168,"title":["Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction"],"prefix":"10.1210","volume":"92","author":[{"given":"Claudio","family":"A\u0301lvarez","sequence":"first","affiliation":[{"name":"Instituto Valenciano de Infertilidad (C.A., E.N.-M., R.G., M.F.-S., C.S., A.P.), University of Valencia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Marti\u0301-Bonmati\u0301","sequence":"additional","affiliation":[{"name":"Department of Radiology (L.M.-B., R.S.), Hospital Quiro\u0301n, 46015 Valencia, Spain"},{"name":"Department of Radiology (L.M.-B.), Hospital Universitario Doctor Peset, University of Valencia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edurne","family":"Novella-Maestre","sequence":"additional","affiliation":[{"name":"Instituto Valenciano de Infertilidad (C.A., E.N.-M., R.G., M.F.-S., C.S., A.P.), University of Valencia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sanz","sequence":"additional","affiliation":[{"name":"Department of Radiology (L.M.-B., R.S.), Hospital Quiro\u0301n, 46015 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rau\u0301l","family":"Go\u0301mez","sequence":"additional","affiliation":[{"name":"Instituto Valenciano de Infertilidad (C.A., E.N.-M., R.G., M.F.-S., C.S., A.P.), University of Valencia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ferna\u0301ndez-Sa\u0301nchez","sequence":"additional","affiliation":[{"name":"Instituto Valenciano de Infertilidad (C.A., E.N.-M., R.G., M.F.-S., C.S., A.P.), University of Valencia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Simo\u0301n","sequence":"additional","affiliation":[{"name":"Instituto Valenciano de Infertilidad (C.A., E.N.-M., R.G., M.F.-S., C.S., A.P.), University of Valencia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pellicer","sequence":"additional","affiliation":[{"name":"Departments of Obstetrics and Gynecology (A.P.), Hospital Universitario Doctor Peset, University of Valencia"},{"name":"Instituto Valenciano de Infertilidad (C.A., E.N.-M., R.G., M.F.-S., C.S., A.P.), University of Valencia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613363646700_R1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMp038106","article-title":"The pathogenesis of the ovarian hyperstimulation syndrome.","volume":"349","author":"Kaiser","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071613363646700_R2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/humupd\/8.6.559","article-title":"Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.","volume":"8","author":"Delvingne","year":"2002","journal-title":"Hum Reprod Update"},{"key":"2020071613363646700_R3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/00313029500169273","article-title":"A fatal case of ovarian hyperstimulation syndrome with cerebral infarction.","volume":"27","author":"Cluroe","year":"1995","journal-title":"Pathology"},{"key":"2020071613363646700_R4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1440-1827.2000.01082.x","article-title":"An autopsy case of ovarian hyperstimulation syndrome with massive pulmonary edema and pleural effusion.","volume":"50","author":"Semba","year":"2000","journal-title":"Pathol Int"},{"key":"2020071613363646700_R5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/humupd\/dmg018","article-title":"Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures.","volume":"9","author":"Aboulghar","year":"2003","journal-title":"Hum Reprod Update"},{"key":"2020071613363646700_R6","first-page":"1723","article-title":"Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro.","volume":"77","author":"Yan","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613363646700_R7","first-page":"1967","article-title":"Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor\/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome.","volume":"80","author":"Neulen","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613363646700_R8","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1210\/jcem.87.7.8651","article-title":"Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor.","volume":"87","author":"Wang","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613363646700_R9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0015-0282(98)00484-1","article-title":"The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1\u03b2, interleukin-6, and vascular endothelial growth factor.","volume":"71","author":"Pellicer","year":"1999","journal-title":"Fertil Steril"},{"key":"2020071613363646700_R10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(94)93001-5","article-title":"Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome.","volume":"344","author":"McClure","year":"1994","journal-title":"Lancet"},{"key":"2020071613363646700_R11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1537-1891(03)00011-9","article-title":"Regulation of vascular permeability by vascular endothelial growth factors.","volume":"39","author":"Bates","year":"2002","journal-title":"Vascul Pharmacol"},{"key":"2020071613363646700_R12","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1074\/jbc.M002016200","article-title":"Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants.","volume":"276","author":"Gille","year":"2001","journal-title":"J Biol Chem"},{"key":"2020071613363646700_R13","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1210\/en.2002-220204","article-title":"Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.","volume":"143","author":"Gomez","year":"2002","journal-title":"Endocrinology"},{"key":"2020071613363646700_R14","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1095\/biolreprod.102.010801","article-title":"Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability.","volume":"68","author":"Gomez","year":"2003","journal-title":"Biol Reprod"},{"key":"2020071613363646700_R15","first-page":"1648","article-title":"Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.","volume":"9","author":"Kuenen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2020071613363646700_R16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1517\/14712598.3.2.263","article-title":"VEGF blocking therapy in the treatment of cancer.","volume":"3","author":"Glade-Bender","year":"2003","journal-title":"Expert Opin Biol Ther"},{"key":"2020071613363646700_R17","first-page":"47","article-title":"Drug treatment of Parkinson\u2019s disease: a practical guide.","volume":"6","author":"Forsyth","year":"2004","journal-title":"CME Geriatr Med"},{"issue":"Suppl 3","key":"2020071613363646700_R18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0015-0282(03)01918-6","article-title":"Tyroxine hydroxylase (TH) downregulation in hyperstimulated ovaries reveals the dopamine agonist bromocriptine (Br2) as an effective and specific method to block increased vascular permeability (VP) in OHSS.","author":"Gomez","year":"2003","journal-title":"Fertil Steril 80"},{"key":"2020071613363646700_R19","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1210\/en.2006-0657","article-title":"Low dose dopamine agonist administration blocks VEGF mediated vascular permeability without altering VEGFR-2 dependent luteal angiogenesis in a rat ovarian hyperstimulation model.","volume":"147","author":"Go\u0301mez","year":"2006","journal-title":"Endocrinology"},{"key":"2020071613363646700_R20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mrm.10045","article-title":"Assessment of hepatic perfusion parameters with dynamic MRI.","volume":"47","author":"Materne","year":"2002","journal-title":"Magn Reson Med"},{"key":"2020071613363646700_R21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S","article-title":"Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols.","volume":"10","author":"Tofts","year":"1999","journal-title":"J Magn Reson Imaging"},{"key":"2020071613363646700_R22","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1210\/jc.2004-2252","article-title":"Age and uterine receptiveness: predicting the outcome of oocyte donation cycles.","volume":"90","author":"Soares","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613363646700_R23","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/humrep\/deg451","article-title":"Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized-controlled study.","volume":"18","author":"Bellver","year":"2003","journal-title":"Hum Reprod"},{"key":"2020071613363646700_R24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: an update review.","volume":"44","author":"Golan","year":"1989","journal-title":"Obstet Gynecol Surv"},{"key":"2020071613363646700_R25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ygyno.2005.08.041","article-title":"Real-time quantitative RT-PCR detection of disseminated endometrial tumor cells in peripheral blood and lymph nodes using the LightCycler System.","volume":"100","author":"Ji","year":"2006","journal-title":"Gynecol Oncol"},{"key":"2020071613363646700_R26","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1186\/gb-2004-5-8-r59","article-title":"Statistical modeling for selecting housekeeper genes","volume":"5","author":"Szabo","year":"2004","journal-title":"Genome Biol"},{"key":"2020071613363646700_R27","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1158\/1078-0432.CCR-04-0059","article-title":"Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis.","volume":"10","author":"Chakroborty","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2020071613363646700_R28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394Ct method.","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"2020071613363646700_R29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/oxfordjournals.humrep.a137613","article-title":"Dopamine treatment for severe ovarian hyperstimulation syndrome.","volume":"7","author":"Ferraretti","year":"1992","journal-title":"Hum Reprod"},{"key":"2020071613363646700_R30","first-page":"281","article-title":"Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine.","volume":"17","author":"Tsunoda","year":"2003","journal-title":"Gynecol Endocrinol"},{"key":"2020071613363646700_R31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejogrb.2005.01.009","article-title":"Cabergoline: a safe, easy, cheap, and effective drug for prevention\/treatment of ovarian hyperstimulation syndrome?","volume":"122","author":"Manno","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2020071613363646700_R32","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/humrep\/16.11.2263","article-title":"Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome.","volume":"16","author":"Papaleo","year":"2001","journal-title":"Hum Reprod"},{"key":"2020071613363646700_R33","doi-asserted-by":"crossref","first-page":"719.e15","DOI":"10.1016\/j.fertnstert.2006.01.055","article-title":"Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas.","volume":"86","author":"Knoepfelmacher","year":"2006","journal-title":"Fertil Steril"},{"key":"2020071613363646700_R34","first-page":"2338","article-title":"Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.","volume":"81","author":"Biller","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613363646700_R35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0890-6238(02)00055-2","article-title":"Pregnancy outcome after cabergoline treatment in early weeks of gestation.","volume":"16","author":"Ricci","year":"2002","journal-title":"Reprod Toxicol"},{"key":"2020071613363646700_R36","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/humrep\/13.9.2406","article-title":"Hematocrit, leukocyte and platelet counts and the severity of the ovarian hyperstimulation syndrome.","volume":"13","author":"Fa\u0301bregues","year":"1998","journal-title":"Hum Reprod"},{"key":"2020071613363646700_R37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/oxfordjournals.humrep.a137103","article-title":"Case report: Acute prerenal failure and liver dysfunction in a patient with severe ovarian hyperstimulation syndrome.","volume":"5","author":"Balasch","year":"1990","journal-title":"Hum Reprod"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/8\/2931\/10404108\/jcem2931.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/8\/2931\/10404108\/jcem2931.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:13:54Z","timestamp":1594944834000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/92\/8\/2931\/2597480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2007-0409","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,1]]}}}